BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Talks.cam//talks.cam.ac.uk//
X-WR-CALNAME:Talks.cam
BEGIN:VEVENT
SUMMARY:Fragment-Based Drug Discovery of Potent and Selective CYP121 Inhib
 itors for Tuberculosis - Madeline Kavanagh
DTSTART:20150308T143000Z
DTEND:20150308T150000Z
UID:TALK58319@talks.cam.ac.uk
CONTACT:George Fortune
DESCRIPTION:Tuberculosis is a re-emerging global epidemic which causes the
  death of more than 1.3 million people annually. Rising levels of antibiot
 ic resistant bacterial strains and co-infection with HIV are key factors d
 riving the resurgence of tuberculosis cases in developed countries\, while
  inadequate hygiene and poor access to health care continue hinder disease
  control in developing   nations. Current treatment regimens for tuberculo
 sis require the co-administration of a cocktail of between 2-10 drugs over
  a 6-24 month period. \nThe drugs cause numerous toxic side-effects\, are 
 difficult to administer and are incompatible with antiretroviral therapies
  for HIV and other co-morbid diseases. Consequently\, patient compliance w
 ith treatment is low\, further accelerating the development of antibiotic 
 resistance. In addition\, the only vaccine available for tuberculosis is i
 neffective in preventing the most common form of the disease in adults. As
  such\, there is dire need for new drugs\, with novel mechanisms of action
 . \n \n This talk will introduce the concepts of fragment-based drug disco
 very using my PhD research on developing inhibitors for the enzymes CYP121
  and CYP144 as examples. The inhibitors developed through this research ha
 ve the potential to be novel treatments for drug-resistant tuberculosis an
 d also enable us to further investigate the biological systems which contr
 ibute to the pathogenicity and virulence of the causal bacterium Mycobacte
 rium tuberculosis. \n
LOCATION:Winstanley Lecture Theatre
END:VEVENT
END:VCALENDAR